MD Anderson experts discuss advances in imaging AI, biomarkers, and proton therapy ahead of the 2025 ASTRO meeting.
Key Details
- 1AI tools are advancing early detection in medical imaging, including lymph node metastases previously missed by standard diagnostics.
- 2Proton therapy is becoming more widespread, with phase III trials (e.g., 440 oropharyngeal cancer patients) showing reduced toxicities versus traditional radiation.
- 3Biomarker research is personalizing prostate cancer care, such as the NRG GU006 trial using genomic tools.
- 4Theranostics and radiopharmaceuticals, like FDA-approved Pluvicto, are expanding from localized to systemic radiation treatments.
- 5MD Anderson researchers are presenting over 65 abstracts at ASTRO covering these innovations.
Why It Matters
AI's integration into medical imaging is quickly improving diagnostic accuracy and treatment personalization in oncology. These advances—especially in clinical trials and real-world applications—are set to directly impact radiology workflows and patient outcomes.
Source
EurekAlert
Related News
•EurekAlert
AI Model Predicts Growth Spurts from Pediatric Neck X-rays for Orthodontics
Korean researchers developed an AI system (ARNet-v2) that predicts children's growth spurts from neck X-rays to enhance orthodontic treatment planning.
•EurekAlert
Dana-Farber Showcases AI and Clinical Trial Advances at ESMO 2025
Dana-Farber researchers present major cancer clinical trial results, including AI-driven data analysis, at ESMO Congress 2025.
•EurekAlert
Einstein College Awarded $18M NIH Grant to Develop AI Tools for Mental Health Crisis Prediction
Albert Einstein College of Medicine received an $18 million NIH grant to create AI-based tools for predicting mental health crises using cognitive monitoring.